Group 1 - The article provides a guide on how to activate and use the online medical insurance (医保) for purchasing medications, emphasizing the importance of activating the electronic medical insurance certificate [2][3]. - It outlines the steps for online ordering and payment using medical insurance, highlighting the necessity to select products marked with "医保" or "医保支付" to ensure eligibility for insurance payment [4]. - The article stresses the implementation of a drug traceability code system to ensure the safety and compliance of purchased medications, with a requirement for all sold drugs to have traceability codes by January 1, 2026 [5]. Group 2 - The online medical insurance purchasing service is gradually being promoted across various regions, and users are advised to check local announcements for specific platform support [6]. - The payment for online medical purchases primarily utilizes the balance in personal medical insurance accounts, generally applicable for purchasing over-the-counter (OTC) medications listed in the medical insurance directory [6].

Core Insights - The year 2025 marks significant advancements in China's healthcare security system, showcasing resilience and a focus on people's health amidst modernization efforts [1] Group 1: Multi-layered Medical Security System - The "1+3+N" framework emphasizes a multi-layered medical security system, including a unified medical insurance information platform, basic medical insurance, major illness insurance, and support for commercial health insurance [2] - Reimbursement rates for inpatient expenses under employee and resident medical insurance have reached approximately 80% and 70%, respectively, with improvements in outpatient services [2] Group 2: Dual Drug Catalogs - The introduction of the "dual catalog" system for basic medical insurance and commercial health insurance marks a significant step in defining the boundaries of coverage, facilitating access to innovative drugs [3] - In 2025, the basic medical insurance catalog added 114 new drugs, with 50 being innovative drugs, achieving a negotiation success rate of 88% [3] Group 3: Provincial Coordination - The push for provincial coordination in basic medical insurance aims to enhance fairness and sustainability, with 20 provinces already advancing this initiative [5] - The focus is on optimizing fund management and ensuring uniform policy implementation across regions [5] Group 4: Anti-Competition Measures - The "anti-involution" strategy aims to stabilize drug pricing and maintain quality by preventing irrational price competition in the pharmaceutical industry [6][7] - Mechanisms have been introduced to ensure fair pricing and enhance clinical selection in drug procurement [7] Group 5: Real-World Research - Real-world research (RWS) has been established as a key tool for evaluating the comprehensive value of drugs and medical technologies, aiming to support sustainable fund management [8] - The National Medical Insurance Administration is developing a nationwide evaluation system to integrate real-world data into decision-making processes [8] Group 6: Long-term Care Professionals - The introduction of long-term care professionals aims to strengthen the workforce for long-term care services, with over 3,500 candidates participating in certification exams across multiple provinces [10] - The long-term care insurance system has expanded to cover nearly 300 million people, benefiting over 3.3 million individuals with disabilities [10] Group 7: Maternity Insurance System - The maternity insurance system aims for "no out-of-pocket" expenses for childbirth within policy coverage, with 2.55 billion people enrolled in the program [11] - Efforts are underway to include more demographics, such as flexible workers and migrant workers, into the maternity insurance coverage [11] Group 8: Drug Traceability Codes - The implementation of drug traceability codes has led to the collection of 39.885 billion codes, enhancing consumer protection and combating counterfeit drugs [13] - By July 2025, all medical institutions will be required to implement full traceability for drug sales [13] Group 9: Three-Settlement Reform - The "three-settlement" reform aims to streamline payment processes in the healthcare sector, significantly reducing the payment cycle for pharmaceutical companies [14] - The initiative includes immediate, direct, and synchronized settlements to enhance service efficiency for patients [14] Group 10: Medical Service Pricing Guidelines - The establishment of national medical service pricing guidelines aims to standardize pricing across provinces, addressing discrepancies and improving service quality [16] - The National Medical Insurance Administration has issued 36 batches of guidelines, with plans to complete 40 by 2026 [16]

Group 1 - The core point of the article highlights the significance of drug traceability codes as unique identifiers for pharmaceuticals, which are crucial in combating drug circulation issues [3] - As of the latest update from the National Healthcare Security Administration, approximately 44.08 billion drug traceability codes have been collected from the production and distribution sectors [3] - Additionally, 101.481 billion drug traceability codes have been collected from designated medical institutions [3]

Core Viewpoint - The implementation of drug traceability codes is crucial for combating counterfeit and returned drugs, with a significant amount of data already collected from various sectors [1] Group 1: Drug Traceability Codes - The National Medical Insurance Administration reports that approximately 44.08 billion drug traceability codes have been collected from the production and distribution sectors [1] - In addition, 101.481 billion drug traceability codes have been collected from designated medical institutions [1] - Starting January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes [1] Group 2: Consumer Access and Implications - Each drug traceability code typically has a single record of sale; multiple scans may indicate counterfeit drugs, returned drugs, or switched sales [1] - Consumers can use the National Medical Insurance Administration's WeChat public account to scan the traceability code on drug packaging to access detailed sales information [1]

Core Viewpoint - The article highlights the significant progress in the collection of drug traceability codes in China, emphasizing the importance of these codes in combating counterfeit and returned drugs. Group 1: Drug Traceability Codes Collection - As of now, approximately 440.8 billion drug traceability codes have been collected from the production and circulation sectors, while designated medical institutions have collected about 1,014.81 billion codes [1] - Starting from January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes [1] Group 2: Types of Drug Traceability Codes - There are three common types of drug traceability codes in China: the "Code on Assurance" traceability code (20-digit barcode), codes set by individual pharmaceutical companies, and the international GS1 coding system, which uses QR codes and is often found on imported drugs [1] - Over 150 countries and regions, along with 116 coding organizations, have joined the GS1 system globally [1] Group 3: Consumer Access to Information - Each drug traceability code typically has a single sales record; multiple scans may indicate counterfeit drugs, returned drugs, or switched sales [1] - Consumers can use the National Medical Insurance Bureau's WeChat public account "Drug Traceability Information Inquiry" to scan the drug traceability code and obtain detailed sales information [1]

Core Viewpoint - The article highlights the importance of drug traceability codes as unique identifiers for pharmaceuticals, which are crucial in combating counterfeit and diverted drugs. The National Healthcare Security Administration (NHSA) has reported significant progress in the collection of these codes, with a mandate for full compliance by 2026 [1] Group 1: Drug Traceability Codes - Drug traceability codes serve as "electronic IDs" for each box of medication, playing a vital role in ensuring drug safety and authenticity [1] - As of now, approximately 440.8 billion drug traceability codes have been collected from the production and distribution sectors, while 1,014.81 billion codes have been collected from designated medical institutions [1] - There are three common types of drug traceability codes in China: the "Code on Assurance" 20-digit barcode, company-specific codes, and the international GS1 coding system, which is often used for imported drugs [1] Group 2: Future Compliance and Consumer Access - Starting January 1, 2026, all medical institutions in China are required to fully collect and upload drug traceability codes [1] - Consumers can access detailed sales information of drugs by scanning the traceability code on the packaging through the NHSA's WeChat public account [1] - The GS1 system has been adopted by over 150 countries and regions, with 116 coding organizations participating globally [1]

Core Viewpoint - The implementation of drug traceability codes is crucial for combating drug circulation issues, with a significant amount of data already collected and a mandate for full compliance by 2026 [1] Group 1: Drug Traceability Codes - Drug traceability codes serve as unique "electronic IDs" for each box of medication, playing a vital role in preventing drug diversion [1] - As of now, approximately 44.08 billion drug traceability codes have been collected from the production and distribution sectors, while 101.481 billion codes have been collected from designated medical institutions [1] - Starting January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes [1] Group 2: Consumer Access - Consumers can access detailed sales information of medications by scanning the traceability code on the drug packaging through the National Medical Insurance Administration's WeChat public account [1]

Core Insights - The article emphasizes the importance of drug traceability codes as unique identifiers for pharmaceuticals, which are crucial in combating counterfeit and diverted drugs [1] - The National Healthcare Security Administration (NHSA) reports that approximately 44.08 billion drug traceability codes have been collected from production and distribution sectors, while 101.481 billion codes have been collected from designated medical institutions [1] - Starting January 1, 2026, all medical institutions in China are required to fully collect and upload drug traceability codes [1] Summary by Categories Drug Traceability Codes - There are three common types of drug traceability codes in China: the "Code on Assurance" 20-digit barcode, self-defined coding standards by some pharmaceutical manufacturers, and the international GS1 coding system, which uses QR codes and is often found on imported drugs [1] - The GS1 system has over 150 countries and regions with 116 coding organizations participating [1] Implications for Consumers - Each drug traceability code typically has a single sales record; multiple scans may indicate counterfeit drugs, diverted drugs, or swapped sales [1] - Consumers can use the NHSA's WeChat public account "Drug Traceability Information Inquiry" to scan the traceability code on drug packaging to access detailed sales information [1]

Core Insights - Guangzhou's healthcare system is enhancing transparency and efficiency through the implementation of a drug traceability code system, which allows citizens to track the source and flow of medications, thereby ensuring clarity in the use of medical insurance funds [1][2] Group 1: Drug Traceability System - The drug traceability code serves as an "electronic ID" for medications and is a crucial component of Guangzhou's healthcare information system, reflecting the city's commitment to improving public welfare through digital reforms [1][2] - As of early December, over 1.2 billion traceability codes have been uploaded, with a daily average of 5 million uploads, showcasing the effectiveness of the system in managing healthcare services [2] Group 2: Systematic Approach to Healthcare Reform - Guangzhou's healthcare reform follows a "step-by-step" approach, starting with retail pharmacies and gradually expanding to more complex medical institutions, ensuring a smooth transition and high-quality implementation [2] - The traceability data is not just numbers; it represents tangible improvements in healthcare services, providing a digital and transparent flow of medication from production to sale [2] Group 3: Data-Driven Healthcare Management - The integration of traceability data with the healthcare settlement system marks a shift from manual verification to a data-driven approach, significantly enhancing service efficiency and accuracy [3][5] - The "data-driven" model allows for real-time verification of traceability codes during medication purchases, streamlining the process for insured individuals [3] Group 4: Collaborative Governance and Public Engagement - Guangzhou's healthcare system promotes a collaborative governance model, involving multiple departments and the public in ensuring the safety of healthcare funds through the traceability system [6] - The system allows citizens to easily access information about their medications, empowering them to act as supervisors of healthcare fund usage [6] Group 5: Future Directions - Guangzhou plans to deepen the integration of drug traceability with healthcare fund supervision and enhance the use of artificial intelligence for risk assessment and trend analysis [6] - The focus remains on improving public health and ensuring the safety of healthcare funds while enhancing the overall experience for citizens in accessing medical services [6]

Group 1 - Starting from July 1, medical insurance designated pharmaceutical institutions must scan the drug traceability code before settling with the medical insurance fund; failure to do so will result in rejection of payment [1] - By January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes [1] - The drug traceability code serves as the "electronic ID" of the drug, ensuring that each box of medication has a unique scanning record, preventing the sale of counterfeit or swapped drugs [1] Group 2 - Consumers can check the sales information of a drug by scanning the traceability code using the National Medical Insurance Bureau's WeChat public account [1] - If a consumer queries and finds "only 1 sales record," it indicates the drug is legitimate; if it shows multiple sales records, it may suggest the drug is counterfeit or has been resold [2][3] - Information obtained from software or apps outside the medical insurance department may not reflect the actual sales settlement information of the drug [3]